The estimated Net Worth of Stanley M Bergman is at least $150 Миллион dollars as of 22 December 2023. Mr. Bergman owns over 56,886 units of Henry Schein stock worth over $32,281,223 and over the last 21 years he sold HSIC stock worth over $103,287,312. In addition, he makes $14,422,900 as Chairman of the Board и Chief Executive Officer at Henry Schein.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Bergman HSIC stock SEC Form 4 insiders trading
Stanley has made over 26 trades of the Henry Schein stock since 2006, according to the Form 4 filled with the SEC. Most recently he sold 56,886 units of HSIC stock worth $4,270,432 on 22 December 2023.
The largest trade he's ever made was selling 179,097 units of Henry Schein stock on 4 December 2012 worth over $14,408,354. On average, Stanley trades about 13,447 units every 71 days since 2003. As of 22 December 2023 he still owns at least 481,450 units of Henry Schein stock.
You can see the complete history of Mr. Bergman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Stanley Bergman biography
Stanley M. Bergman serves as Chairman of the Board, Chief Executive Officer of the Company. He has been with the Company since 1980, including as Chairman and Chief Executive Officer since 1989 and as a director since 1982. He is also a member of our Executive Management Committee. Mr. Bergman held the position of President of the Company from 1989 to 2005. Mr. Bergman held the position of Executive Vice President from 1985 to 1989 and Vice President of Finance and Administration from 1980 to 1985. Mr. Bergman brings to the Company’s Board of Directors management and leadership experience. Mr. Bergman is a well-known, highly regarded leader in the global health care industry. He has expansive knowledge of the health care industry and macro-economic global conditions, maintains strategic relationships with chief executives and other senior management in the health care industry throughout the world and brings a unique and valuable perspective to the Board of Directors. During his tenure, Mr. Bergman has led the Company from sales of $600 million in 1995 to $12.5 billion in 2017. Mr. Bergman serves as a board member or advisor for numerous institutions, including New York University College of Dentistry, the University of Pennsylvania School of Dental Medicine, the Columbia University Medical Center, Hebrew University, Tel Aviv University, the University of the Witwatersrand Fund, the World Economic Forum’s Health Care Governors and the Business Council for International Understanding. Mr. Bergman is also a member of the boards of numerous charitable organizations and active with philanthropic causes and social responsibility activities. Mr. Bergman is a Certified Public Accountant.
What is the salary of Stanley Bergman?
As the Chairman of the Board и Chief Executive Officer of Henry Schein, the total compensation of Stanley Bergman at Henry Schein is $14,422,900. There are no executives at Henry Schein getting paid more.
How old is Stanley Bergman?
Stanley Bergman is 70, he's been the Chairman of the Board и Chief Executive Officer of Henry Schein since 2005. There are 6 older and 27 younger executives at Henry Schein. The oldest executive at Henry Schein Inc. is Barry Alperin, 79, who is the Independent Director.
What's Stanley Bergman's mailing address?
Stanley's mailing address filed with the SEC is C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE, NY, 11747.
Insiders trading at Henry Schein
Over the last 22 years, insiders at Henry Schein have traded over $272,732,340 worth of Henry Schein stock and bought 23,637 units worth $1,414,559 . The most active insiders traders include Stanley M Bergman, Norman S Matthews и Deborah Derby. On average, Henry Schein executives and independent directors trade stock every 21 days with the average trade being worth of $1,074,342. The most recent stock trade was executed by Lorelei Mc Glynn on 6 September 2024, trading 21,035 units of HSIC stock currently worth $1,457,726.
What does Henry Schein do?
henry schein, inc. is the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners. the company also serves dental laboratories, government and institutional health care clinics, and other alternate care sites. a fortune 500® company and a member of the s&p 500® and nasdaq 100® indexes, henry schein employs more than 18,000 team schein members and serves more than one million customers. the company offers a comprehensive selection of products and services, including value-added solutions for operating efficient practices and delivering high-quality care. henry schein operates through a centralized and automated distribution network, with a selection of more than 100,000 branded products and henry schein private-brand products in stock, as well as more than 150,000 additional products available as special-order items. the company also offers its customers exclusive, innovative technology solutions, including practice
What does Henry Schein's logo look like?
Complete history of Mr. Bergman stock trades at Henry Schein
Henry Schein executives and stock owners
Henry Schein executives and other stock owners filed with the SEC include:
-
Stanley Bergman,
Chairman of the Board, Chief Executive Officer -
Stanley M. Bergman,
Exec. Chairman & CEO -
Steven Paladino,
Chief Financial Officer, Executive Vice President, Director -
Gerald Benjamin,
Chief Administrative Officer, Executive Vice President, Director -
James Breslawski,
President, Vice Chairman of the Board, Director -
Mark Mlotek,
Chief Strategic Officer, Executive Vice President, Director -
James P. Breslawski,
Exec. Vice Chairman & Pres -
Gerald A. Benjamin,
Exec. VP, Chief Admin. Officer & Exec. Director -
Steven Paladino,
Exec. VP, CFO & Exec. Director -
Mark E. Mlotek,
Exec. VP, Chief Strategic Officer & Exec. Director -
Michael Racioppi,
Senior Vice President, Chief Merchandising Officer -
Philip Laskawy,
Lead Independent Director -
Barry Alperin,
Independent Director -
Joseph Herring,
Independent Director -
Kurt Kuehn,
Independent Director -
Bradley Sheares,
Independent Director -
Carol Raphael,
Independent Director -
Anne Margulies,
Independent Director -
Elizabeth Rekow,
Independent Director -
Shira Goodman,
Independent Director -
Paul Brons,
Independent Director -
James Mullins,
Senior Vice President of Global Services -
Rene Willi,
President, Global Dental Surgical Group -
David Brous,
President, Strategic Business Units Group and Asia Pacific & Brazil Dental -
Steven Kess,
President of the Santa Fe Group -
Carolynne Borders,
Vice President - Investor Relations -
Jonathan Koch,
Senior Vice President and Chief Executive Officer, Global Dental Group and Interim Chief Executive Officer, Henry Schein One -
Michael Ettinger,
Senior Vice President - Corporate and Legal Affairs, Chief of Staff, Secretary -
Lorelei McGlynn,
Chief Human Resource Officer -
Walter Siegel,
Senior Vice President, General Counsel -
Christopher Pendergast,
Senior Vice President, Chief Technology Officer -
Brad Connett,
President - Henry Schein's U.S. Medical Group -
Olga Timoshkina,
VP of Corp. Fin., Chief Accounting Officer & Corp. Controller -
Michael Saul Ettinger,
Exec. VP & COO -
Ronald N. South,
Sr. VP & CFO -
John Lee,
VP of Global Compensation & Benefits -
Walter Siegel,
Chief Legal Officer -
Graham Stanley,
VP of Investor Relations & Strategic Fin. Project Officer -
Christopher Pendergast,
Sr. VP & CTO -
Ronald South,
Chief Accounting Officer & VP of Corp. Fin. -
Paul Rose,
SVP, Global Supply Chain -
David Mc Kinley,
President, Medical Group -
Donald J Kabat,
Director -
Karen Prange,
EVP&CEO Gl.AH.Med.Den.Sur.Grp -
Lawrence S Bacow,
Director -
Robert Minowitz,
President, Int'l Dental Group -
E Dianne Rekow,
Director -
Peter M. Mc Carthy,
Pres., Global Animal Health -
Bridget A Ross,
President, Global Medical Grp -
James A. Harding,
Chief Technology Officer -
Mohamad Ali,
-
Deborah Derby,
-
Michael Zack,
Senior Vice President -
Larry Gibson,
Executive V.P. and CTO -
Irving Shafran,
Director -
Margaret A Hamburg,
Director -
Marvin Schein,
-
Pamela Joseph,
Director -
Stanley Komaroff,
Senior Advisor -
Lonnie Shoff,
Pres., Global Healthcare Spec. -
Norman S Matthews,
Director -
Louis W Sullivan,
Director -
Karyn Mashima,
Director -
Leonard A David,
Vice President -
Reed Vaughn Tuckson,
-
Scott Philip Serota,
-
Carole T Faig,
-
Ronald N. South,
SVP & Chief Financial Officer